The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma
Source: MDLinx, March 2021
This study was undertaken to explore the effectiveness of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma. Between 2012 and 2018, researchers conducted a single institution, retrospective cohort study included patients with advanced acral melanoma (AM) and mucosal melanoma (MM) who had undergone anti-programmed cell death protein 1 (PD-1) therapy for metastatic melanoma.
